Drugs / VAX125
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00730457 | Jul 2008 → Mar 2009 | influenza | VaxInnate Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00966238 | Sep 2009 → Apr 2010 | influenza | VaxInnate Corporation | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAX125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00730457 ↗ |
| Known as | STF2.HA1(SI) | “STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its...” NCT00966238 ↗ |
| Action | Activate | “TLR-5 agonist” PMID 21596084 ↗ May 2011 |
| Modality | Vaccine | “recombinant hemagglutinin influenza-flagellin fusion vaccine” PMID 20969925 ↗ Oct 2010 |
| Route | Intramuscular | “administered intramuscularly (im)” PMID 20969925 ↗ Oct 2010 |
| Target | TLR5 | “a Toll-like receptor 5 (TLR5) ligand” NCT00966238 ↗ |